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ABSTRACT 
Marine sponges represent an excellent source of sphingolipids and their metabolites, 
especially sphingosine-1-phosphate (S1P). S1P plays an important role in cell differentiation, 
survival, proliferation and the immune response. The enzyme sphingosine kinase (SK) is critical 
for the phosphorylation of sphingosine to S1P and has been examined as a druggable target for 
the treatment of hyper-proliferative diseases, inflammation, cancer and other pathological 
conditions. Natural products that consist of an azetidine ring represents an interesting class of 
conformationally constrained scaffolds that may serve as effective lead compounds for SK 
inhibitor development.  Hence, the goal of this thesis research was to synthesize natural-product 
based sphingosine analogs from easily accessible precursors.   
Our initial approach was to synthesize azetidine from the commercially available 
cinnamyl alcohol. The described synthetic methodology is proficient and scalable for the 
synthesis of fully substituted azetidines. We were successful at preparing two azetidine analogs, 
(±)-30 and (±)-31, via an intramolecular Mitsunobu reaction as a key step. Another crucial 
technique is the Grubbs’ cross-metathesis reaction to the side-chain extension. This reaction 
provides an opportunity to develop various analogs through side-chain modification. Compound 
(±)-30 was synthesized in 11 steps and compound (±)-31 was synthesized in 10 steps with 
affordable overall yield. The described synthetic methodology represents a promising tool for the 
invention of various analogs of the natural products and the synthesized compounds will serve as 
lead compounds for the future optimizations.  
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I. INTRODUCTION 
 
The diversity of plant and animal species in marine environments represent unique 
sources in the discovery and development of novel drugs.
1,
 
2,
 
3
 Marine natural products began to 
receive attention in 1951 when the unknown nucleosides, spongouridin and spongothymidin, 
were isolated from the sponge Cryptotethya crypta.
3
 More than 20,000 compounds were isolated 
from marine sources since the 1960s.
3
 In addition, marine sponges are excellent sources of lipids, 
terpenes and alkaloids. To prevent predation and for security from infection, sponges generate 
cytotoxic compounds. More than 10% marine sponge species have engendered cytotoxic activity 
which implies that they are an efficient source for the production of effective medicines.
2,
 
4
 The 
pharmaceutically active compounds found in sponges include immunomodulators, anticancer, 
anti-viral, antifouling, and antimalarial agents. Unfortunately, only a few of these compounds 
have resulted in marketed drugs due to the limited production of sponge biomass and trace 
amounts of the desired bioactive compounds in sponges.
4,
 
5
  In order to understand the biological 
activity of marine sponges and further develop a bioactive compounds into a commercialized 
product, constant supply is a prerequisite. The supply issue is the major problem in the field of 
marine natural products. However, advanced technologies such as improved sampling 
techniques, fermentation, total synthesis and biotechnology have resolved this critical issue. A 
feasible tactic for the total synthesis of bioactive natural products has provided the large-scale 
production and allowed to develop SAR and lead optimization studies. However, marine natural 
2 
 
products often possess complex chemical structures with well-defined stereochemistry. 
Therefore, it is difficult to synthesize compounds with extraordinary spatial orientation.
6,
 
7
  
Secondary metabolites from marine sponges are well-known for their protein kinase 
inhibitory activity, with more than 70 compounds identified with promising activity and 
selectivity. For instance, lasonolide A from Forecpia sp., hymenialdisine from Axinella 
verrucosa, variolin B from Kirkpatrickia varialosa, hymenialdisines from Stylissa massa and 
liphagal from Aka coralliphaga produce significant activities against various kinases.
2
 Protein 
kinases are a superfamily of enzymes that are ubiquitous among animal, plant and bacteria 
kingdoms, and their altered production or mutations are involved in diverse diseases, such as 
cancer, Alzheimer’s disease and atherosclerosis.2 The human genome contains over 500 protein 
kinases, representing approximately 1.7% of human genes.
8,
 
9, 10
 Protein kinases catalyze the 
addition of phosphate group from adenosine triphosphate (ATP) to a specific amino acid 
substrate. The covalent bond formed between phosphate group and amino acid substrates are 
provided by the hydroxyl group of serine/threonine or tyrosine. Hence, protein kinases are 
recognized as serine/threonine kinases or tyrosine kinases depending on the specific amino acid 
substrates.
2, 9 
Furthermore,
 
protein kinases play critical roles in regulating cellular processes such 
as cell proliferation, metabolism, transcription, differentiation, cell movement, cell survival and 
apoptosis. Deregulation and mutation of protein kinases are linked to diseases such as, cancer, 
immune system disorders, osteoporosis, central nervous system diseases, and metabolic 
disorders. More than 130 protein kinase inhibitors are either in Phase I or Phase II clinical trials 
and the majority are being evaluated against different types of cancer.
2,
 
10,
 
11
  
Sphingolipids  are components of the cell walls or cell membranes and are engaged in a 
variety of biological processes including cell differentiation, growth, proliferation, apoptosis and 
3 
 
the immune response.
12,
 
13
 Sphingosine is recognized as an effective and reversible inhibitor of 
protein kinase C (PKC). PKC is activated by the presence of Ca
2+
 or diacylglycerol as shown in 
Figure 1. It is also triggered by tumor-promoting phorbol esters. The activation of PKC is related 
to its intracellular translocation from the cytoplasm, and consequently down regulation via 
proteolytic cleavage of PKC. PKC is involved in the phosphorylation of membrane-related 
proteins. Sphingosine hinders the translocation and down regulation of PKC. Inhibition of PKC 
by sphingosine is competitive with diacylglycerol and phorbol esters and non-competitive with 
Ca
2+
.
8, 14, 15, 16 
   
 
 
 
4 
 
     
Figure 1. Schematic illustration of signaling pathways for sustained PKC 
activation. Adapted from ref.
8
 (PIP2-phosphatidylinositol-4,5-bisphosphate; 
PC-phosphatidylcholine; PLC-phospholipase C; PLD-phospholipase D; 
PLA2-phospholipase A2; PA-phosphatidic acid; DAG-diacylglycerol; PKC-
protein kinase C; IP3-Inositol trisphosphate) 
 
Sphingosine was discovered by the German physician and neurochemist Johann Ludwig 
Wilhelm Thudichum.
17, 18
 Sphingosine is an unsaturated monoaminodihydroxy alcohol and was 
origionally obtained from the hydrolysis of phrenosin (Figure 2).
18
 It is metabolized to 
sphingosine-1-phosphate (S1P) which is a potent signaling molecule.
19
  S1P has been identified 
in many organisms such as plants, yeast, worms, flies and mammals.
20,
 
21
 In mammals, it is 
produced and secreted from the platelets.
22
 S1P is a major component of serum and its 
approximate concentration is 400 nM. It is also secreted from specific cells, like mast cells, 
5 
 
monocytic cells and red blood cells. It is bound to serum albumin in plasma and has been 
detected in high density lipoproteins and oxidized low density lipoproteins. However, the 
mechanisms of secretion at cellular levels are still an enigma. It has also been detected in 
numerous organ systems such as, gastrointestinal, reproductive, pulmonary, and endocrine. 
Studies indicate that  S1P is engaged in physiological regulation of many organ systems.
22
 It 
stimulates signaling pathways by binding to five different receptor subtypes expressed as S1P1-5 
which are the constituents of the endothelial differentiation gene (EDG). EDG is a family of G 
protein-coupled receptors (GPCRs).
23
 S1P1 and S1P5 activate mainly Gi, S1P2 activates all G 
proteins, S1P3 activates Gi, Gq, and G12/13, and S1P4 couples to Gi and G12 in response to S1P. As 
a result, S1P involves in various biological functions depending on S1P receptor subtypes and G 
proteins.
20,
 
24
 S1P regulates cell migration, proliferation, and angiogenesis via activating 
extracellular signal-regulated kinase (ERK)1/2, phosphoinositide 3-kinase (PI3K), phospholipase 
C (PLC), Ras and Rho-dependent pathways.
25
 However, the biological activities of S1P 
receptors still remain elusive. 
 
Figure 2. Structure of sphingosine and sphingosine-1-phosphate, adapted from ref.
26
  
 
1.1 PATHWAY FOR BIOSYNTHESIS AND METABOLISM 
OF SPHINGOSINE-1-PHOSPHATE 
Understanding the intracellular regulation of S1P demands a description of the various 
enzymes responsible for its synthesis and metabolism. Sphingosine and ceramide are required for 
the production of S1P; sphingosine kinases (SKs) are responsible for the metabolism of 
6 
 
sphingosine to S1P. Sphingosine is produced from the metabolism of sphingolipids and the 
deacylation of ceramide. There are two routes that engage in the production of ceramide: the first 
is the de novo biosynthesis pathway of sphingolipids; the second is the endocytic recycling 
pathway of sphingolipids.
19, 20      
The de novo sphingolipid biosynthesis pathway is prevalent among cells and tissues; loss 
of function by mutation of the enzyme serine palmitoyltransferease (SPT) can affect cell growth 
and development. The de novo pathway initially involves the condensation of L-serine and 
palmitoyl CoA to afford 3-ketodihydrosphingosine (KDS) as shown in Figure 3. This reaction 
takes place at the cytosolic leaflet of the endoplasmic reticulum. It is the rate-limiting reaction 
and is catalyzed by SPT, essential for the management of sphingolipid levels in cells. KDS, 
produced from SPT, is quickly converted to dihydrosphingosine by 3-ketodihydrosphingosine 
reductase. Dihydrosphingosine is N-acylated to produce dihydroceramide catalyzed by the 
enzyme ceramide synthase. Dihydroceramide is then desaturated to form ceramide by the 
enzyme dihydroceramide desaturatase. Ceramide is subsequently converted to sphingosine by 
the enzyme ceramidase, which is then phosphorylated to S1P by SK (Figure 4). 
19, 20, 27, 28, 26 
The 
decomposition of S1P is facilitated by two different routes: the reversible dephosphorylation of 
S1P to sphingosine by the enzyme S1P phosphatases and the irreversible inactivation of S1P to 
hexadecenal and phosphoethanolamine by a pyridoxal phosphate-dependent S1P lyase. 
Hexadecenal and phosphoethanolamine are the precursors for phosphatidylethanolamine 
biosynthesis.
21
 
In the endocytic sphingolipid recycling pathway, the enzymes sphingomyelinases are 
responsible for hydrolyzation of sphingomyelin to ceramide and phosphorylcholine. There are 
three different types of sphingomyelinases, characterized based on their pH optima into acidic, 
7 
 
neutral, and alkaline forms. Acidic sphingomyelinases are expressed in the lysosomal 
compartment, while neutral sphingomyelinases are expressed in the plasma membrane, 
endoplasmic reticulum, Golgi, and nucleus. Alkaline sphingomyelinases are mainly expressed in 
the intestinal tract and the bile. Several studies have suggested that stress factors and 
proinflammatory cytokines can increase sphingomyelinase activity and ceramide levels which 
lead to cell death. Like sphingomyelinases, ceramidases also have three different forms such as 
acidic, neutral, and alkaline forms, that deacylate ceramide to sphingosine.
19
  
8 
 
 
 
Figure 3. Biosynthesis of ceramide, adapted from ref.
27, 29
  
 
9 
 
 
Figure 4. Biosynthesis and metabolism of sphingosine and S1P, adapted from ref.
21, 29
 
 
1.2 SPHINGOSINE KINASE (SK) 
SK is the key enzyme in the transformation of sphingosine to S1P. There are two 
isoforms of SK, SK1 and SK2. The high level of SK1 is detected in lung and spleen, whereas SK2 
is found in liver and heart.
30
 Three different splice isoforms of SK1 have been detected in 
10 
 
humans, SK1a, SK1b, and SK1c. These isoforms vary only at their N-terminal regions. As shown 
in figure 5, SK1b contains 14 additional amino acids whereas SK1c contains 86 additional amino 
acids compared to SK1a.  There are two isoforms of SK2, SK2a and SK2b, with SK2b having 36 
additional amino acids than SK2a.
29
 Surprisingly, the structural features of SK are not fully 
understood. 
 
Figure 5. Schematic representation of human sphingosine kinase isoforms. 
Reprinted with permission from Elsevier (Trends Biochem Sci, 2011. 36(2): p. 97-
107).
29
 
 
All identified SKs contain five highly conserved regions, denoted as C1–C5. These 
conserved regions are believed to be involved in protein structure management and the binding  
of substrates.
31
 For instance, GLY82 in conserved regions of SK1 is essential for catalysis 
whereas ASP278 is essential for substrate binding. The other domains of SK1 contain 
Ca
2+
/Calmodulin, TRAF2 and the conserved ATP binding site.
32
  Moreover, a nuclear export 
signal is found  in SK1 while the C-terminus in SK2 contains a proline rich domain, nuclear 
localization signal and an SH3 binding motif.
31
 SK1 have residues that attach to acidic 
phospholipids and phosphatidylserine. SK1 is found mostly in the cytosol, where it is 
translocated to the plasma membrane and subsequently phosphorylated by ERK. The outcome of 
S1P signaling depends on SK1 subcellular localization.
32
 In animal model, targeting SK1 was 
shown to decrease the occurrence and complexity of disease, while targeting SK2 was shown to 
11 
 
increase the progression of disease. This implies that SK1 and SK2 play different roles under 
normal or disease conditions.
29
 
 
1.3 FUNCTION OF SPHINGOSINE-1-PHOSPHATE 
1.3.1 Effect of S1P on the vascular system. 
High concentrations of S1P have been detected in plasma and serum. S1P participates 
in signal transduction using the GPCRs found on vascular endothelial and smooth muscle 
cells. S1P is involved in the activation of endothelial cells that lead to production of an 
imperative messenger, nitric oxide (NO) (Figure 6).
22
 NO stimulates the soluble isoform of 
guanylate cyclase (sGC) in the vascular smooth muscle cells, which in turn generates the 
messenger molecule cyclic guanosine monophosphate (cGMP). cGMP production promotes 
the vasorelaxation responses induced by S1P actions. In contrast, S1P also stimulates S1P2 
and S1P3 receptors on vascular smooth muscle cells which in turn activate the small G-protein 
RhoA, Rho-associated protein kinase (ROK) and PKC. Stimulation of the RhoA/ROK/PKC 
route promotes the vasoconstriction responses induced by S1P receptors.
33
 This suggests that 
S1P can act as a vasoconstrictor or a vasorelaxor depending on the expression patterns of S1P 
receptor subtypes in endothelial cells and vascular smooth muscle cells. A number of studies 
revealed that S1P1 receptor on endothelial cell regulates vascular maturation and induces 
endothelial cell proliferation. This suggests that S1P is a powerful controller of 
angiogenesis.
22, 33, 34
  
 
 
 
12 
 
 
Figure 6. Schematic representation of role of S1P in vascular system, adapted 
from ref.
33
 (Rac1-Ras-related C3 botulinum toxin substrate 1; NO - nitric oxide; 
eNOS - endothelial isoform of NO synthase; RhoA - Ras homolog gene family, 
member A; ROK - Rho-associated protein kinases; GC - soluble isoform of 
guanylate cyclase; cGMP - cyclic guanosine monophosphate)  
 
1.3.2 Effect of S1P on the central and peripheral nervous system. 
S1P receptors have been identified in the central and peripheral nervous system. For 
example, the white matter, hippocampus and the cerebellum express high levels of S1P1 receptor. 
Astrocytes (specialized glial cells) and Purkinje cells (cerebellum) also express high level of 
S1P1 receptors. However, the function of S1P1 in Purkinje cell is poorly understood.
22,
 
35
 S1P is 
involved in neurite rounding, growth cone collapse and axonal collapse processes that are 
imperative for the development of neuronal pathways.
22,
 
36
 This indicates that S1P may play a 
role in the development and remodeling of the CNS. In the peripheral nervous system, S1P 
13 
 
receptors have been detected in glial cells. In vitro studies imply that S1P prevents apoptosis of 
Schwann cells (which prevents apoptosis of glial cells) by the PI-3-kinase/Akt signaling 
pathway. This suggests that S1P may have a crucial role in the nervous system; however its 
function in the CNS and PNS is poorly understood.
22
 
1.3.3 Effect of S1P in inflammation. 
S1P is abundant in platelets and has been detected in other cell types including 
neutrophils, erythrocytes, and mononuclear cells.
23
 These cells can release S1P via activation of 
growth factor receptors, G-protein-coupled receptors, and cytokine receptors. The released S1P 
produces various physiological actions, such as, inflammatory responses (Figure 7). Mounting 
evidence reveals that S1P plays an essential role in inflammatory process since S1P1 and S1P2 
receptors are detected in mast cell and may regulate mast cell activation. S1P1 receptors also  are 
involved in mast cell migration, whereas S1P2 receptors are engaged in degranulation.
37
 
The cyclooxygenases, COX-1 and COX-2, are oxidative enzymes involved in 
prostaglandin synthesis. COX-2 facilitates inflammatory events in response to the cytokines 
interleukin-1β and tumor necrosis factor-α (TNF-α). In certain cell types, TNF elevates 
intracellular levels of ceramide via stimulating the endocytic recycling pathway of sphingolipid 
(sphingomyelin hydroxylation) and/or triggering the de novo biosynthesis pathway. In many 
cells, TNF activates S1P production by stimulating the enzyme SK.
38
 S1P stimulates cytosolic 
phospholipase A2 (cPLA2) and releases arachidonic acid through S1P3 receptor-mediated 
increase of intracellular calcium and Rho kinase activation. Arachidonic acid is oxygenated to 
prostaglandins which are involved in a number of physiological and pathological processes.
30
 
This suggests that S1P may have a role in pathological inflammatory diseases.
38
      
14 
 
 
Figure 7. Schematic representation of role of sphingolipids in inflammation, 
Adapted from ref.
37
 (C1P - ceramide 1-phosphate; c/EBP - CCAAT/enhancer 
binding proteins; COX-2 - cyclooxygenase-2; cPLA2 - cytosolic phospholipase 
A2; LPS - lipopolysaccharide; NF-ĸB - nuclear factor-ĸB; S1P - sphingosine 1-
phosphate; SK - sphingosine kinase; SMase - sphingomyelinase; TNF - tumor 
necrosis factor-α.)  
 
1.3.4 Effect of S1P in cancer. 
Several reports have documented the finding that S1P plays a significant role in the 
development of tumor growth. In addition, elevated amount of SK mRNA has been observed in 
tumors of uterus, ovary, breast, colon, stomach, and lung.
39, 40 
The equilibrium between 
ceramide, sphingosine and S1P stipulates a rheostat model. According to this mechanism, a cell 
is directed to apoptosis through ceramide and sphingosine signaling or is survives by S1P.
41, 42
 
15 
 
SK is critical checkpoint enzyme in the rheostat model since it transfers death-supporter 
sphingolipids such as ceramide and sphingosine, into the growth-supporter S1P. Cancer cells 
make good use of rheostat by fostering circumstances that encourage the formation of S1P. 
Various cancer cells attain this through the enzyme SK1 suggesting that SK1 could be a possible 
oncogene.
42
 Furthermore, studies suggest that inhibition of SK1 decreases tumor angiogenesis, 
growth, and chemoresistance in various xenograft models, whereas overexpression of SK1 
increases these events.
43
  
In the tumor microenvironment, S1P is released by blood platelets, fibroblasts, and mast 
cell. Tumor cells enhance expression of SK, which in turn augment the level of S1P in the tumor 
microenvironment (Figure 8). The produced S1P from tumor cells act in an autocrine fashion to 
enhance growth, cell migration, survival and metastatic potential of tumor cells or in a paracrine 
fashion to encourage endothelial cell based angiogenesis and regulate lymphangiogenesis and 
immune cells.
42, 43, 44
 In addition, S1P enhances cancer development through intracellular targets 
including HDAC1/2 and NF-ĸB and also supports cancer cells to resist therapy. Recent studies 
revealed that S1P1 receptor activates signal transducer and activator of transcription-3 (STAT3) 
in cancer cells and in the tumor microenvironment which is crucial for cancer development and 
metastasis. S1P production is also able to enhance proangiogenic growth factors such as vascular 
endothelial growth factor (VEGF), IL-6 and IL-8 from tumor cells. Taken together, S1P 
modulators represent a central target in the treatment of cancer.
42,
 
43
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Figure 8. Schematic representation of role of S1P in cancer. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Publishing Group. (British 
Journal of Cancer, 2006. 95(9): p. 1131-35).
42
 (SPH-Sphingosine; SPHK-
Sphingosine kinase; VEGF-vascular endothelial growth factor; IL-6- Interleukin 
6; IL-8- Interleukin 8) 
 
1.3.5 Effect of S1P on the reproductive system. 
S1P receptors are detected in some cells of the testes and the ovaries. In the male, S1P1 is 
detected in the seminiferous tubule of the testicle and this receptor has been expressed by mature 
spermatid during the preparation of spermatogenesis. Moreover, S1P is involved in the inhibition 
of the male germ cells apoptosis. S1P has an ability to protect the initial phases of 
spermatogenesis suggesting that S1P inhibits the sperm cell loss induced by radiation.
22, 45, 46
 In 
the female, the oocyte apoptosis and female infertility is induced by cytotoxic chemotherapy 
treatment. S1P inhibits the oocyte apoptosis. Although, S1P may engage in the male and female 
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germ cells, but the further studies are required to investigate the mechanism of S1P in 
reproductive system.
22
 
 
1.4 MEDICINAL APPROACHES TO TARGET S1P PATHWAYS 
Cancer cells release S1P that are proficient to bind S1P receptors on endothelial cells and 
foster cell proliferation that leads to tumor neovascularization. In tumors, S1P can also work on 
fibroblasts through growth factors that may nurture cancer development. Hence, S1P receptors 
antagonists might be proficient to impede fibrosis, neovascularization and proliferation of cancer 
cells. Furthermore, a compound with SK1 inhibitory activity might bolster apoptosis of cancer 
cells and fibroblasts. Thus, a compound with dual activity would be tremendously beneficial to 
prevent cancer expansion.
47
 Several therapeutic approaches have been developed to control S1P 
signaling in cancer such as production of S1P-specific antibodies, agonizing/antagonizing 
specific S1P receptors, and targeting SK1 and/or SK2 enzymes.
41
  
1.4.1 S1P-specific antibodies. 
Prevention of cancer using S1P-specific antibodies is a nascent approach in the S1P 
research arena. The anti-S1P antibodies work as “molecular sponges” to reduce S1P from blood 
and other compartments. They nullify extracellular tumor supporting growth factors which lead 
to lower their bioavailability.
48
 A recently established murine monoclonal antibody, LT1002, 
known as Sfingomab, has high binding affinity and specificity for S1P. This anti-S1P 
monoclonal antibody has shown anti-neovascularization effects, minimized tumor progression as 
well as lowered tumor vascularization by inhibiting vascular endothelial growth factor in several 
in vivo and in vitro assays.
49
 LT1009, the humanized variant of LT1002, known as 
Sonepcizumab, also has high binding affinity and specificity for S1P and it is as effective as 
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LT1002. S1P plays an imperative role in the lymphocyte trafficking between blood and 
lymphoid tissue. The intravenous administration of LT1002 and LT1009 was shown to decrease 
numbers of circulating lymphocytes in in vivo study.  Currently LT1009 is in Phase 1 clinical 
trial for the treatment of cancer and age-related macular degeneration (AMD). It was formulated 
as ASONEPTM
 
for cancer and iSONEPTM for AMD. In Phase 1 clinical trial, LT1009 was tested 
against patients with different types of solid tumors such as prostate, renal, ovarian, colorectal, 
and breast. It has been revealed that LT1009 decrease the tumor progression for around 8-12 
months in majority of patients. Based on the successful results in cancer patients, LT1009 is 
being selected for Phase II clinical trials. As such, this anti-S1P monoclonal antibody could be a 
marketable drug that would be very beneficial for the patients who are battling against life-
threatening disease such as cancer.
41, 48, 50,
 
51
   
1.4.2 SK inhibitors. 
In cancer cells, it is imperative to reduce S1P signaling. SK is an essential enzyme that 
catalyzes the production of S1P. Drug discovery efforts have been focused on identifying new 
and selective inhibitors of SK1 and SK2. The structures of several SK inhibitors are shown in 
Figure 9 and their properties are shown in Table 1. The first non-lipid small molecule SK 
inhibitor reported was 2-(p-hydroxyanilino)-4-(pchlorophenyl) thiazole, also recognized as SKi 
or SKI-II, a non-specific inhibitor. SKi was shown to reduce the production of S1P, inhibit 
proliferation and generate apoptosis in many tumor cell lines. It also showed good bioavailability 
and minimization of tumor progression in in vivo studies.
32,
 
47
 Structural editing of SKi led to 
discovery of SKi-178 which is selective inhibitor of SK1. SKi-178 is more potent and less 
cytotoxic than the parent molecule.
32
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Figure 9. Structures of SK inhibitors, adapted from ref.
32, 51,
 
52,
 
53
  
 
The first selective SK1 inhibitor discovered was (2R,3S,4E)-N-methyl-5-(4’-
pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as BML-258; a water soluble sphingosine 
analogue. It did not demonstrate any inhibitory effects on SK2, PKC, or various other cellular 
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kinases. BML-258 reduced tumor growth and survival and induced apoptosis in human leukemia 
cell lines. It also inhibited the phosphorylation of Akt and ERK1/2 and decreased the growth of 
acute myelogenous leukemia xenograft tumors.
54
 A selective non-lipid SK2 inhibitor developed 
is 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide, also known as 
ABC294640. ABC294640 was shown to prevent cell proliferation and migration in tumor cell 
lines. It also showed excellent oral bioavailability and promoted tumor cell autophagy that 
generated non-apoptotic cell death and reduced tumor growth in several in vivo studies.
55,
 
56
   
D,L-threo-dihydrosphingosine (D,L-threo-DHS) is the synthesized form of natural D-
erythro-dihydrosphingosine. D,L-threo-DHS functions as an inhibitor of SK1 and functions as a 
substrate for SK2.
32
 L-threo-DHS, also known as safingol, is the first SK1 inhibitor that has been 
used in clinical trials for the treatment of cancer. It showed enhanced cytotoxic effects when used 
in combination with other anticancer agents.
51
 N,N-dimethylsphingosine (DMS) is another non-
specific inhibitor of SK activity. It also interferes with PKC, 3-phosphoinositide-dependent 
kinase, and casein kinase II. It was shown to reduce tumor growth and induce apoptosis in 
several studies.
41, 56
 
There are reports of natural products such as F-12509A, B-5354c, S-15183a, and S-
15183b that have shown good SK inhibitory activity in vitro, but their specificity for SK 
isoforms is vague and their large-scale production is dubious.
41, 56
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 Table 1. Sphingosine kinase inhibitors and their characteristics 
SK 
Inhibitors 
Mechanism 
of action 
Type of 
Inhibition 
Comments 
SKi 
Inhibit SK1 
and SK2 
Non- 
Competitive 
Stimulates cathepsin-B-mediated 
degradation of SK1, no effects on PKC, 
ERK and PI3K.
32,
 
41
 
SKi-178 
Inhibit SK1 Competitive 
Addition of methyl and methoxy groups 
to the parent compound led to reduce 
cytotoxicity and increase selectivity for 
SK1.
32
 
BML-258 
Inhibit SK1 Competitive 
Suppressed tumor growth, decreased 
proliferation, and induced apoptosis in 
the tumor.
54
 
ABC294640 Inhibit SK2 Competitive 
Showed good pharmacological profiles, 
anticancer activity, anti-inflammatory 
activity and low toxicity in in vivo & in 
vitro studies.
55
 
D,L-threo-
DHS 
Inhibit SK1 Competitive Inhibits other kinases.
32
 
DMS 
Inhibit SK1 
and SK2 
Competitive for 
SK1/Non- 
Competitive for 
SK2 
Lack of specificity, inhibit various other 
cellular kinases.
56
 
PF543 Inhibit SK1 Competitive Inhibits S1P formation in whole blood.
57
 
F-12509A 
(Natural 
product) 
Inhibit SK1 
and SK2 
Competitive 
Isolated from a dicomycete 
Trichopezizella barbata , induce 
apoptosis.
41
 
B-5354c 
(Natural 
product) 
Inhibit SK1 
and SK2 
Non- 
Competitive 
Isolated from a marine bacterium, 
decreased S1P production in human 
platelets.
41, 52
 
S-15183a and 
S-15183b 
(Natural 
product) 
SK 
(Specificity 
not 
determined) 
Not determined 
Isolated from a fungus Zopfiella 
intermis, decreased S1P production in in 
vitro studies.
41
 
 
1.4.3 S1P receptor modulators. 
Recently, the discovery for S1P therapeutics has emphasized compounds which have the 
ability to target specific S1P receptors. In particular, the unique immunosuppressant indicated for 
the treatment of multiple sclerosis, fingolimod (GilenyaTM) or FTY720, is phosphorylated 
through SK2 and the resulting phosphorylated FTY720 acts as an agonist or partial agonist for all 
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types of S1P receptors except S1P2.  FTY720 has low affinity for S1P2. There are five different 
types of S1P receptors including S1P1, S1P2, S1P3, S1P4, and S1P5.
58, 59, 60 
FTY720 is the first 
oral drug for the treatment of multiple sclerosis, and it was approved by FDA in 2010.
51
 FTY720 
easily crosses the blood–brain barrier and produces several responses in the CNS. Multiple 
sclerosis is an inflammatory disease in which lymphocytes move out of lymph nodes and 
circulate throughout the body and damage myelin sheath of neurons that lead to inflammation, 
demyelination, neuroaxonal injury, and neurodegeneration. S1P is detected in the lymph and 
serum. The high concentration of S1P (found in circulation) is responsible for lymphocytes 
migration into the circulation. Fingolimod is structurally similar to S1P and down-regulates S1P 
receptors on T cells. As a result, lymphocytes remain sequestered in the lymph node.
61
 
Moreover, FTY720 was shown to induce apoptosis in various cancer cell lines such as prostate, 
liver, lung, breast and bladder.
62,
 
63
 It also reduced tumor growth and metastasis without any 
noticeable toxic side effect in a mouse melanoma model. In ovarian cancer cells, FTY720 was 
shown to promote autophagy and cell death via caspase 3-independent necrotic pathways.
62, 63
 It 
inhibits ERK1, ERK2, and Akt phosphorylation, and activates caspases, JNK, and PKCδ.
41
 
The success of FTY720 has provided proof-of-principal evidence that selective S1P 
receptor modulators have clinical value in disease management. The structures of the S1P 
agonists and antagonists are illustrated in Figure 10. SEW2871 was the first selective S1P 
receptor agonist discovered. Structurally, it differs from S1P; hence there is no need of 
phosphorylation for receptor binding. In animal studies, this compound was shown to produce 
lymphopenia. CYM-5442 is another selective S1P1 receptor agonist. Like SEW2871, there is no 
need of phosphorylation for receptor binding. KRP-203 is an S1P1 receptor agonist, but also has 
the ability to bind and activate other receptors such as S1P1, S1P4 and S1P5. VPC01091 is 
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phosphorylated by SK2 and acts as an agonist or partial agonist for S1P1, S1P4 and S1P5 receptors 
and antagonist for S1P3 receptor.
60
  
There are several selective S1P receptor antagonists that have been discovered in recent 
years. VPC44116 is a competitive S1P1 receptor antagonist and is less potent for the S1P3 
receptor, and has the ability to act as a partial agonist at S1P4 and S1P5 receptors. The prodrug 
VPC03090 is a S1P1/3 receptor antagonist. It is phosphorylated by SK2 and the resulting 
phosphorylated VPC03090 acts as an antagonist for S1P1 and S1P3 receptors, and an agonist or 
partial agonist for S1P4 and S1P5 receptors. JTE-013 was developed as an S1P2 receptor 
antagonist whereas CAY10444 is selective S1P3 receptor antagonist. W146 is an S1P1 receptor 
antagonist whereas its enantiomer, W140, has less affinity for the S1P1 receptor. However, none 
of these compounds have superior profiles and further studies are required to reveal the potential 
of these antagonists.
60
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Figure 10. Structures of S1P receptor agonists and antagonists, adapted from ref.
60
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1.5 CRYSTAL STRUCTURE OF THE GPCR S1P1 RECEPTOR 
Recently, the crystal structure of the S1P1 receptor has been solved. The crystal structure 
of the S1P1 receptor will serve as a valuable tool for medicinal chemists to construct more 
selective small molecule modulators of the S1P1 receptor, and this will be advantageous for 
designing and understanding the agonistic and antagonistic functions of other S1P receptors.
64
 
The crystallization was carried out by fusing the S1P1 receptor to a T4-lysozyme in complex with 
the selective antagonist (R)-3-amino-(3-hexylphenylamino) - 4-oxobutylphosphonic acid 
(ML056). The resultant crystalized receptor has seven trans-membrane helices organized in a 
conserved bundle.
60, 65
 There are three extracellular loops (ECL) including ECL1, ECL2 and 
ECL3 as shown in Figure 11.  
 
Figure 11. Structural features related to S1P1 receptor. Reprinted with 
permission from the American Association for the Advancement of Science 
(Science, 2012. 335(6070): p. 851-55).
65
 (ECL1, ECL2 and ECL3 are shown in 
gold, orange and yellow ribbon respectively. ML056 is illustrated in green ball 
and stick model.) 
 
There are two important features of the crystal structure of the S1P1 receptor. First, the N-
terminus folds over the ECL1and ECL2 to form a helical cap that confines the extracellular 
access to the amphipathic binding pocket. The ECL1 and ECL2 are tightly packed against the N-
26 
 
terminus helix. S1P obtains access to the binding pocket from within the membrane bilayer, 
probably via a gap between transmembrane helices I and VII.  Second, the development of a 
cluster of positively charged and polar residues created by helices III and VII, ECL 2 and the N- 
terminal cap, furnish a high affinity interaction to the phosphate group of the sphingolipid.  The 
information obtained from the crystal structure of S1P1 receptor may help to construe and 
determine the crystal structure of other S1P receptors.
60, 65
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II. SYNTHETIC METHODOLOGIES TOWARDS  
SPHINGOSINE DERIVATIVES 
 
2.1 INTRODUCTION AND THE PURPOSE OF REASERCH 
Heterocyclic sphingoid secondary metabolites have been isolated from marine sources, 
For instance, in 1991 Kobayashi et al. isolated the sphingosine relatives, penaresidin A and B, 
from the marine sponge penares sp. that were characterized as actomyosin ATPase-activators.
66, 
67
 Crews and coworkers isolated penazetidine A from the marine sponge Penares sollasi in 1994, 
structurally related to the penaresidins and was identified as a relatively potent protein kinase C 
(PKC) inhibitor.
68
 The crude extract of this marine sponge showed an IC50 = 0.3 μg/mL against 
PKCβ1 while it was inactive against protein tyrosine kinases. Furthermore, penazetidine A 
exhibited substantial activity against PKC (IC50 = l μM), and  displayed considerable in vitro 
cytotoxicity against murine and human cancer cell lines.
2, 69
 The structures of penaresidin A / B 
and penazetidine A are shown in Figure 12. These compounds have received attention due to 
their unique structure and interesting biological activity. There are several total synthesis 
described in the literature; however, the protocols suffer from poor stereo control and lengthy 
reaction sequences.
70
 Therefore, the goal of this thesis research is to develop new methodologies 
for the construction of the azetidine ring with emphasis on preparing sphingosine analogs from 
readily available precursors. Natural products that consist of an azetidine ring represents an 
intriguing class of conformationally constrained scaffolds that may serve as valuable lead 
compounds for SK inhibitor development.    
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Figure 12. Structures of azetidine alkaloids, adapted from ref. 
70
 
 
The quest for biologically active compounds from marine origins has revealed that 
sponges represent a rich resource for novel protein kinase inhibitors.
2
 The azetidine ring, a four 
membered ring comprising a nitrogen atom, is found as a substructural element in a number of 
natural products. Azetidine ring-containing compounds exhibit various biological activities, such 
as antihypertensive, anticonvulsant, analgesic, antiepileptic, and anticancer. For instance, ABT-
594 demonstrates more potent analgesic activity compared to that of morphine.
71
 Although 
azetidines are important substructures in drug discovery and lead optimization, they are 
synthetically challenging to construct, particularly with substitutions on the azetidine ring 
system. Huszthy et al., reported, “azetidines are one of the most difficult amines to synthesize 
because of the unfavorable enthalpy of activation in four-membered ring formation and the high 
susceptibility to cleavage of the strained hetero ring”.72 Since the parent azetidine was first 
synthesized in 1888 in impure form, it has been challenging for synthetic chemists to discover 
new and efficient methods for their construction. There are several conventional methods
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reported and usually involve an intramolecular displacement of a leaving group from the γ-amino 
nucleophile. The most reliable and often used chemistry protocols are described in Scheme 1.  
These cyclizations can also be achieved by the reduction of an azido group using Raney-nickel, 
palladium on carbon (Pd/C) or using other reducing agents. It has also been reported that the 
Mitsunobu reaction offers a robust method to form azetidines from protected NH precursors.
71
  
 
Scheme 1. Schematic representation of the formation of azetidine  
 
2.2 EXPLORATORY STUDIES 
The inspiration for synthesis of azetidine derivatives as sphingosine analogs originated 
from the identification of the PKC inhibitor, penazetidine A. We hypothesized that azetidines 
could be derived from commercially available cinnamyl alcohol. The Prilezhaev’s epoxidation 
protocols
73
 would produce enantiomeric epoxides that could be elaborated to the aminodiol with 
subsequent cyclization to azetidines. As shown in Scheme 2, the cyclization of 1 was carried out 
by treatment with various reducing agents (10% Pd/C, lithium aluminum hydride and 
triphenylphosphine (PPh3)) to afford 2. We also attempted form the azetidine ring by treatment 
of 3 with NaH to afford 4 and 5. However, the procedures used for the formation of azetidine 
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suffered from low yield and undesired side products. Moreover, it was problematic to deal with 
purification process during the synthesis and was also difficult to introduce key alkyl group on 
the C-4 carbon of the azetidine ring system. Hence, efforts towards these initial reaction 
protocols were discontinued.   
 
Scheme 2. Initial synthetic approaches for the formation of azetidine  
 
It was realized that modification of the amine protecting group, particularly with N-
sulfonyl group, may offer an advantage with the ring cyclization chemistry. The resultant 
sulfonamide is the strong electron-withdrawing agent due to the sulfonyl group and it is weak 
acid which upon reaction with weak base eliminates the leaving group and undergo cyclization.
74
 
As shown in Scheme 3, cyclization of 6 was carried out by treatment with K2CO3 to afford 7.
75
 
The synthetic protocol described in Scheme 3 afforded azetidine 7 in excellent yield.  
 
Scheme 3. Synthetic pathway for the formation of azetidine  
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2.3 RESULT AND DISCUSSION 
We believed that a proficient technique could be developed toward the synthesis of target 
compound 30 using an intramolecular cyclization approach. The retrosynthetic analysis of 30 is 
depicted in Scheme 4. Compound 30 was envisioned to be derived from a Grubbs’ cross-
metathesis reaction
73
 of a long chain alkene with the vinyl substituted 27A. The azetidine ring 
would be formed from a Mitsunobu reaction
76
 of 25 using a suitable amine protecting group, 
namely, a sulfonamide. Compound 25 would be prepared from the precursor alcohol 21 via 
oxidation and subsequent Grignard reaction.
77
 The protected amino diol 21 would be synthesized 
from cinnamyl alcohol using epoxidation and amine ring opening reactions.    
 
Scheme 4. Retrosynthetic analysis of (±)-30 
 
The synthesis began with the formation of known epoxy alcohol 8 from cinnamyl alcohol 
using the Prilezhaev reaction.
73
 Typically, meta-chloroperoxybenzoic acid (m-CPBA) is the 
preferred peroxyacid for the formation of epoxides from alkene precursors. This reaction is 
reported to be stereospecific, and the product obtained was isolated in 89% yield in racemic 
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form, which was used without purification.
73,
 
78
 Scheme 5 summarizes the epoxidation of 
cinnamyl alcohol.  
 
Scheme 5. Epoxidation of cinnamyl alcohol 
 
Initially, we performed a regiochemical ring opening reaction of epoxide 8 using sodium 
azide to afford azido alcohol 9. The reduction of azide 9 with triphenhylphosphine and water 
(Staudinger reaction) and subsequent N-protection of the resulting amine with tert-
butoxycarbonyl anhydride to yield 10 was carried out in a single step (Scheme 6).
79
  
 
Scheme 6. Ring opening of epoxy alcohol using sodium azide.  
 
The next step was the selective protection of the primary over the secondary alcohol to activate 
the primary alcohol as a leaving group (tosyloxy) for the formation of azetidine ring system. The 
reaction was carried out by treatment of 1,2-diol 10 with catalytic  dibutyltin oxide (n-Bu2SnO) 
with removal of water to produce tin acetal 11. Compound 11 undergoes sulfonylation in the 
presence of p-toluenesulfonyl chloride (TsCl) at the primary position to afford selective 
monotosylate 13 in 71% yield. As shown in Scheme 7, the tin acetal 11 activates the primary 
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alcohol and temporary protects secondary alcohol to produce selective monotosylate 13 with 
high regioselectivity in a single operation.
80, 81 
 
Scheme 7.  Protection of primary and secondary alcohol 
 
With 13 in hand, the protection of secondary alcohol was conducted by treatment of 13 
with tert-butyldimethylsilyl triflate (TBS-OTf) and 2,6-lutidine to afford TBS-protected alcohol 
3. Surprisingly, we observed that TBS-OTf is not only protecting the secondary alcohol but also 
replacing the N-Boc group to N-tert-butyldimethylsilyloxycarbonyl group (silyl carbamate, 
(Scheme 7)). The N-Boc group can be activated by fluoride ion that would react with an 
electrophile to produce silyl carbamate type compound.
82
 The structure of compound 3 was 
confirmed by MS, 
1
H-NMR and 
13
C-NMR analysis. Diagnostic signals in the proton NMR 
spectrum of compound 3 (δ 0.91 – 0.88 (d, J = 9.7 Hz, 18H), 0.27 – 0.23 (d, J = 17.1 Hz, 6H), 
0.05 – 0.04 (d, J = 3.1 Hz, 6H)) clearly indicated that the N-Boc group of 13 was converted to 
silyl carbamate group (Figure 13).  
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Figure 13. 
1
H-NMR spectrum of (±)-3 
 
After protection, the cyclization reaction of 3 was performed in the presence of sodium 
hydride (NaH) to afford azetidine 4. Interestingly, another product was formed from this 
reaction, namely, the five-membered cyclic carbamate 5 (Scheme 8). It is known that silyl 
carbamates can serve as nucleophiles and participate in substitution reactions with  
electrophiles.
83
 Activation of the N-carbamate of 4 with sodium hydride afforded 4 and 5 in an 
SN2 manner; this would result in inversion of stereochemistry if the leaving group was a 
functionalized secondary alcohol.
84
 The proposed mechanism for the conversion of cyclic 
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carbamate 5 is shown in Figure 14. Products were confirmed based on TLC and MS analysis. 
Due to the instability of silyl carbamate 4, it was problematic to purify using silica gel column 
chromatography.     
 
 
Scheme 8. Cyclization of (±)-3 & MS spectrum of (±)-4 and (±)-5 
 
 
Figure 14. Proposed mechanism for the formation of (±)-5 
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Although this protocol provided good yields and stereocontrol, the N-Boc group had no 
significant impact on the formation of azetidine. Moreover, problems occurred during synthesis 
and prevented the expansion of further chemistry. In order to understand the role of different N-
protecting groups on the formation of azetidine, it became necessary to investigate alternative 
methods earlier in the synthesis. 
Pastó M. et al. reported an outstanding method for the efficient synthesis of vicinal amino 
alcohols from precursor epoxides. The vicinal amino alcohol motif is a structural pharmacophore 
in a variety of natural products and therapeutics many of which comprise various biological 
activities.
85,
 
86
 Furthermore, a free amino group renders the opportunity of utilizing diverse N-
protecting group tactics (e.g. N-Ts or N-Ns) in the synthesis of amino acids and biomolecules. 
With 8 in hand, the ring-opening of epoxy alcohol was investigated by treatment of 8 with 
ammonia in the presence of isopropyl alcohol to afford amino alcohols in excellent yield 
(Scheme 9). This reaction is safe, inexpensive, stereospecific and regioselective, hence, furnishes 
a greener alternative to the typical two- or three-step reaction sequences involving either the use 
of poor atom-economic conditions such as benzhydrylamine or the use of hazardous reagent such 
as azide.
85, 87
 The obtained product was converted to the hydrochloride salt by treatment with an 
HCl saturated solution of methanol to yield 14 in excellent yield. The product was confirmed 
based on LC-MS, 
1
H-NMR and 
13
C-NMR analysis. 
 
Scheme 9. Ring opening of epoxy alcohol using ammonia 
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An alternate protecting group strategy was employed, to overcome the obstacles using an 
N-carbonate protecting group in earlier synthetic attempts. We selected to employ an N-sulfonyl 
protection of the amine as a reasonable group, due to its stability and lack of O-alkylation or 
group transfer reactions.
88
 We attempted several N-sulfonylation methods but all the procedures 
involved the formation of desired product with undesired N,O-disulfonylated compound as a side 
product (Scheme 10). In a typical procedure, the amine salt 14 was treated with 2-
mesitylenesulfonyl chloride in the presence of diisoproylethylamine (DIEA) to afford 
sulfonamide 15 in good yield. The low yield was attributed to competing sulfonylation of the 
hydroxyl groups, which were partially suppressed with conducting the reaction at 0 
o
C. 
 
 
Scheme 10. Sulfonylation of amine salt (±)-14 & MS spectrum of (±)-15 and (±)-16 
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The next step was to selectively oxidize the primary alcohol in order to produce a method 
to install various R-groups in advance of ring cyclization strategies. We attempted several 
oxidation methods, but none of them proved useful in selective oxidation of the primary over the 
secondary alcohol. The procedures used for formation of the aldehyde suffered from over-
oxidation and was problematic to deal with product purification. The products described in 
Scheme 11 were confirmed based on TLC and MS analysis.  
 
 
Scheme 11. Oxidation of alcohol & MS spectrum of (±)-17, (±)-18 and (±)-19 
 
For these reasons, we chose an alternate strategy to generate the desired aldehyde 
product, which invoked a dual protection and selective mono-deprotection strategy. Silylation 
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was achieved by reaction of 15 with tert-butyldimethylsilyl chloride in DMF and imidazole to 
afford bis-silylated 20 in excellent yield (Scheme 12).
89
 
 
Scheme 12. TBS protection of diol 
 
The next step involved the selective deprotection of the primary TBS-protected alcohol.  
Accordingly, 20 was treated with THF/TFA/H2O (4:1:1) at room temperature to yield 21 in good 
yield. To enhance yield while preserving the secondary TBS-protected alcohol, the reaction 
mixture was constantly monitored. The reaction was stopped when the production of bis-silyl 
deprotected product was observed and the remaining starting material was consumed.
90,
 
91
 In 
order to evaluate the impact of the sulfonamide group, initially we directed our efforts towards 
the formation of the azetidine using Mitsunobu reaction conditions (Scheme 13). In this attempt, 
21 was treated with PPh3 and diisopropyl azodicarboxylate (DIAD) to afford 22.
76
  
 
Scheme 13. Deprotection of primary TBS-protected alcohol & ring formation. 
 
The success of the Mitsunobu reaction paved the way for introduction of alkyl side chains 
via Grignard reactions using aldehyde precursors.
92
 We attempted to oxidize 21 to 23 using a 
variety of oxidation methods, including Swern oxidation
93
 and Parikh-Doering oxidation
94
 
methods. However, the low yields coupled with the formation of side products were observed 
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during the synthesis (Scheme 14). Furthermore, the resulting product aldehyde was prone to 
decomposition upon silica gel purification.  
 
 
Scheme 14. Oxidation of alcohol & MS spectrum of (±)-23 and (±)-24 
 
Saito et al. reported an efficient and selective method for oxidation of primary achohols to 
aldehydes using 2-iodoxybenzoic acid (IBX).
95
 Therefore, compound 21 was treated with IBX in 
the presence of DMSO at RT to afford 23 in excellent yield (Scheme 15). The obtained product 
was taken to the next step without silica gel purification, in order to circumvent decomposition 
chemistry. The 
1
H-NMR spectral profile clearly indicated that compound 23 is an aldehyde not a 
ketone or carboxylic acid (Figure 15). IBX was prepared by treatment of 2-iodobenzoic acid with 
Oxone in presence of deionized water in 85% yield. This method is convenient, non-hazardous 
and environmentally safe.
96
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Scheme 15. Oxidation of alcohol using IBX  
 
 
Figure 15. 
1
H-NMR spectrum of (±)-23 
 
After successfully synthesizing the key aldehyde 23, vinylation was carried out using 
Grignard reaction conditions. The reaction was performed by treatment of 23 with 
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vinylmagnesium bromide to afford 25 in 81% yield and diastereomeric ratio of 5:1 (Scheme 16). 
Since the addition of Grignard reagents occurs on both faces of the carbonyl group of aldehyde, 
the prochiral aldehyde induces diastereomeric mixtures of the resultant alcohols.
73,
 
97
 The 
resulting isomers were purified and taken to the next step as a mixture. 
Stereoselective addition of various organometallics such as In, Sn, and Zn to prochiral 
carbonyls in the presence of aqueous medium has been scrutinized from synthetic and 
mechanistic perspectives.
98,
 
99
 Therefore, 23 was treated with Zn dust & allyl bromide in the 
presence of aqueous NH4Cl to afford 26 in excellent yield (Scheme 16). This Zn-mediated 
Barbier-type reaction
98
 is faster and the isolation of the product is straightforward. The 
diastereomeric products were separated using silica gel chromatography, and characterized using 
spectroscopic techniques.  
  
Scheme 16. Vinylation and allylation of aldehyde 
 
The Mitsunobu reaction is an adaptable and frequently used approach for the dehydrative 
coupling of an acid or nucleophile (or pro-nucleophile) with an alcohol by using reducing 
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phosphine reagent such as PPh3 and an oxidizing azo reagent such as DIAD or DEAD.
100
 The 
nucleophilic addition of PPh3 to DIAD produces a phosphonium intermediate that binds to the 
alcohol and activates it as a leaving group. The deprotonated sulfonamide displaces the leaving 
group (phosphine oxide (Ph3PO)) and completes the ring formation. The resultant azetidine has 
inverted stereochemistry due to the presence of secondary alcohol in starting material.
100,
 
101,
 
102
 
The diagrammatic representation of the mechanism of the Mitsunobu reaction is outlined in 
Figure 16. The intramolecular ring closure reaction of 25 was investigated by treatment with 
PPh3 and DIAD in the presence of THF.
76
  The reaction produced two major products, 27A and 
27B.   
 
Figure 16. Mechanism of Mitsunobu reaction, adapted from ref. 
73,
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Aryl azetidine (27) represents the key intermediate towards the synthesis of final 
compounds. Diastereomers were separated by column chromatography (Scheme 17).  
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Scheme 17. Ring closure reaction of (±)-25 
 
The structure elucidation of 27A and 27B was investigated by MS and NMR 
spectroscopic techniques. The molecular weights of 27A and 27B are identical and were 
confirmed on the basis of their MS spectra, with a [M+Na]
+
 m/z 494. The 
1
H-
1
H 2D COSY NMR 
spectrum disclosed correlations between protons at δ 4.75 – 4.73 (H2), 4.50 – 4.46 (H4), 3.95 – 
3.92 (H3) for 27A and δ 5.13 – 5.12 (H2), 4.88 – 4.85 (H4), 4.37 – 4.35 (H3) for 27B of azetidine 
ring. The correlation between carbons and protons was determined by 2D HMQC and HMBC 
experiments. The 
13
C-NMR data of 27A and 27B are δ 76.77(C2), 71.71(C4), 69.72(C3) and 
74.41(C2), 73.41(C4), 72.52 (C3), respectively. The NMR spectral profile clearly indicated that 
27A and 27B are fully substituted azetidines. The difficulty of determining the configuration of 
azetidine alcohol by 1D or 2D NOE spectral analysis has been reported due to the vicinity of the 
H2 and H4 proton resonances. Hence, the configurational assignment has been determined by 
their coupling constants values. The cis isomers usually show higher coupling constants values 
than the corresponding trans isomers.
103,
 
104
 It was confirmed based on J-values that 27A is a 
trans-isomer and 27B is cis-isomer.  The J-values are shown in Figure 17.  
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Figure 17. J- Values of compound (±)-27A and (±)-27B 
 
The next step was to perform an olefin cross-metathesis reaction on the azetidine 
precursors in order to extend the scope of the chemistry in the production of analogs. Olefin 
cross-metathesis reactions are efficient techniques to introduce carbon-carbon double bonds with 
homologation. Ruthenium carbenoids (Grubbs’ Catalyst) are favorably active catalysts for 
different types of olefin-metathesis reactions. These catalysts work very well for electron-
deficient and sterically demanding olefins.
105
 Commonly used catalysts are depicted in Figure 
18.   
 
Figure 18. Commonly used catalysts for olefin cross metathesis, adapted from ref.
106
 
 
A Grubbs’ 2nd generation catalyst was chosen as preferred catalyst for our cross 
metathesis reactions because of its tremendous functional-group tolerance, simplicity to control 
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under ambient condition, a satisfactorily high rate of reaction propagation, and commercial 
availability.
106
 The general mechanism of cross metathesis is illustrated in Figure 19. 
 
Figure 19. Mechanism of olefin cross metathesis, adapted from ref.
105
 
 
With 27A in hand, the cross metathesis reaction was conducted by treatment of 27A with 
Grubbs’ 2nd generation catalyst and tridecane providing 28 in modest yield. The important aspect 
of the cross metathesis reaction is the cis:trans (E/Z) selectivity. It is well-stated in the literature 
that longer reaction times usually lead to higher quantities of trans-olefin products (Scheme 
18).
106
 The resultant product was identified by MS and NMR spectroscopic methods. 
 
Scheme 18. Olefin cross-metathesis reaction of (±)-27A 
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The final step in the synthesis included the deprotection of N-sulfonyl group by reaction 
with sodium naphthalenide and subsequently deptrotection of TBS group by 
tetrabutylammonium fluoride (TBAF), affording 30. The product was converted to the 
hydrochloride salt by treatment with methanolic HCl (Scheme 19).  
In order to determine the influence of N-sulfonyl group on biological activity, the 
deprotection of silyl group on 28 was achieved by treatment with TBAF to afford 31. The final 
products were confirmed by MS, 
1
H-NMR and 
13
C-NMR evaluation. The synthesized azetidine 
analogs (30 and 31) may act as SK inhibitors and/or S1P receptor modulators. This synthetic 
strategy we employed is very efficient and scalable with the flexibility to introduce a variety of 
functionality and route to analog synthesis.   
 
Scheme 19. Deprotection of (±)-28 
 
2.4 BIOLOGICAL INVESTIGATION 
Among the synthesized compounds, (±)-30 and (±)-31 were selected for biological evaluation as 
potential SK inhibitors. Dr. Daniel Baker and his colleagues at the University of Memphis are 
currently testing these derivatives as SK1 inhibitors.  
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2.5 CLOSING THOUGHTS  
The research described documents an efficient and practical route for the synthesis of 
2,3,4-trisubstituted azetidines using the intramolecular Mitsunobu reaction as key method for 
creating the azetidine ring. We were successful at preparing and structurally verifying two 
azetidine analogs, (±)-30 and (±)-31, each of which display structural resemblance to other 
natural sphingosine analogs.     
The key to this synthetic pathway invoked is the use of the weak acid N-sulfonyl group as 
a nucleophile in the intramolecular Mitsunobu reaction. The nucleophilic sulfonamide displaces 
the activated alcohol as phosphine oxide and completes the azetidine ring formation.  Another 
imperative approach in this synthesis is the Grubbs’ cross-metathesis reaction for side-chain 
elongation. This reaction provides an opportunity to develop various analogs through side-chain 
modification by using simple alkenes.    
Although the total synthesis of penazetidine A was not completed, the key intermediate 
((±)-27) represents a promising compound for constructing this natural product and its analogs.  
Several problems were encountered and overcome during this thesis research. The first and 
foremost was the selection of a proper N-protecting group. The use of an N-sulfonyl group 
overcomes the problem associated with azetidine ring formation. The described synthetic 
methodology will stimulate opportunities to develop various azetidine analogs as a lead 
compounds for not only for sphingosine kinase, but also for other pertinent biological targets.  
 
2.6 FUTURE DIRECTIONS  
Since the synthesis was performed in racemic fashion, it was difficult to ascertain the 
impact of stereochemistry on biological activity. To resolve stereochemistry issues it will be 
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necessary to repeat the synthetic pathways using Sharpless asymmetric epoxidation (SAE)
73
 as a 
first step to install chirality. The attractive feature of this reaction is the use of (+) or (-)-diethyl 
tartrate to afford enantioenriched epoxides with more than 90% enantiomeric excess.
73,
 
107, 108
 
Penazetidine A can be synthesized using this Sharpless epoxide product as a starting material. 
The possible synthetic pathway for penazetidine A is outlined in Scheme 20. Yajima and 
coworkers synthesized penazetidine A in 6% overall yield in eighteen steps.
68
 Our proposed 
synthetic methodology will lead to the production of penazetidine A in eleven steps from 
commercially available cinnamyl alcohol.  
 
Scheme 20. Proposed synthetic route for penazetidine A  
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III. EXPERIMENTAL 
General methods: 
Cinnamyl alcohol was purchased from Sigma Aldrich. All chemicals, catalysts, reagents and 
solvents used for reaction and chromatography were purchased at the best commercial grade. 
Moisture-free reactions were carried out in oven or flame dried glassware in the presence of 
argon using dry solvents. Tetrahydrofuran (THF) was purified and dried by sodium metal and 
benzophenone (indicator) using distillation technique. Dichloromethane (CH2Cl2) was purified 
and dried by distillation process in the presence of calcium hydride. Anhydrous dimethyl 
sulfoxide (DMSO), N,N-dimethylformamide (DMF) and dimethoxyethane (DME) were 
purchased from Sigma Aldrich and used without further purification. Thin layer chromatography 
(TLC) was carried out on aluminum backed silica gel 60 F254 coated TLC sheets with UV 254 
from EMD Chemicals Inc. Flash column chromatography was obtained using a   SiliaFlash® 
P60 40-63µm 60Å Silica Gels from SiliCycle Inc. 1D and 2D NMR spectra were recorded on 
either Bruker Advance DRX 400 (400 MHz) or Bruker Advance DRX 500 (500 MHz) 
spectrometers. 
1
H NMR coupling patterns are designated as singlet (s), doublet (d), triplet (t), 
(quartet (q), double doublet (dd), double double doublet (ddd), double triplet (dt), multiplet (m). 
Mass spectrometry (MS) data were recorded using electrospray ionization (ESI) on a Waters 
Micromass ZQ mass spectrometer.  Elemental Analysis was determined using a PerkinElmer 
2400 Series II CHNS/O Analyzer. Melting points were detected on a Mel-Temp Apparatus. 
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General procedure for Epoxidation: 
 
Using an adapted method of Balamurugan, et al.,
109  
to
 
a solution of cinnamyl alcohol (74.52 
mmol, 1 equiv.) in dry CH2Cl2 (300 ml), m-CPBA (111.78 mmol, 1.5 equiv.) was added. After 2 
h of continuous stirring at RT, 50 ml of saturated aqueous Na2SO3 solution was added to the 
reaction mixture and stirred for another 15 min. Then the resultant mixture was washed twice 
with saturated aqueous NaHCO3 and brine. The organic layer was separated, dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to afford epoxide 8 as a white solid in 
89% yield. The desired product was used in the next step without purification. ESI-MS: m/z 
173.085 [M+Na]
+
, 
1
H NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 5H), 4.02 – 3.98 (dd, 1H), 3.90 
(s, 1H), 3.77 –3.73 (dd, J = 12.7, 4.1 Hz, 1H), 3.22 – 3.20 (m, 1H), 2.96 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 136.69, 128.53, 128.34, 125.79, 62.66, 61.40, 55.75; DEPT-135 (101 MHz, 
CDCl3) δ 128.53, 128.34, 125.79, 62.66, 61.40, 55.75. 
 
Using an adapted method of Venkatesan, et al.,
110
 epoxide 8 (26.63 mmol, 1 equiv.), NaN3 
(53.26 mmol, 2 equiv.) and NH4Cl (56.26 mmol, 2 equiv.) were added to a solvent mixture of 
methanol (29 ml) and water (5 ml) and warmed at 65 °C for 8 h. The resultant mixture was 
cooled to RT and filtered. The filtrate was concentrated in vacuo and the residue was diluted 
with EtOAc, extracted two times with water and brine. The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (70% petroleum ether / EtOAc; stains orange with p-anisaldehyde) to 
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afford azido diol 9 as a yellow oily liquid in 80% yield. ESI-MS: m/z 216.201 [M+Na]
+
, 
1
H 
NMR (400 MHz, CDCl3) δ 7.41 – 7.32 (ddd, J = 19.6, 13.2, 7.2 Hz, 5H), 4.57 – 4.55 (d, J = 7.1 
Hz, 1H), 3.82 – 3.78 (m, 1H), 3.68 – 3.60 (m, 2H), 3.05 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 
136.10, 128.94, 128.78, 127.81, 74.03, 67.00, 62.88.   
 
Using an adapted method of  Kimura et al.,
79
 to a solution of azido diol 9 (1.4518 mmol, 1 
equiv.) in THF (4.8 ml) was added PPh3 (1.4518 mmol, 1 equiv.) under an atmosphere of argon. 
The reaction mixture was stirred at RT for 10 min. and water (0.32 ml) was added. After 5 h of 
continuous stirring at 60 °C, it was cooled to RT. Thereafter, di-tert-butyl dicarbonate (1.5969 
mmol, 1.1 equiv.) was added and stirred at RT for 2 h. The resultant mixture was concentrated in 
vacuo and the crude product was purified by column chromatography (80% EtOAc/ether; stains 
purple with ninhydrin) to afford N-Boc protected diol 10 as a white solid in 90% yield. ESI-MS: 
m/z 290.15 [M+Na]
+
, 
1
H NMR (400 MHz, MeOD) δ 7.36 – 7.23 (m, 5H), 4.70 – 4.68 (d, 1H), 
3.86 – 3.82 (q, J = 5.8 Hz, 1H), 3.54 – 3.50 (dd, J = 11.8, 4.3 Hz, 1H), 3.46 – 3.42 (dd, J = 11.3, 
5.8 Hz, 1H), 1.42 (s, 9H), 1.28 (s, 2H); 
13C NMR (101 MHz, MeOD) δ 156.35, 139.91, 127.74, 
127.43, 126.80, 78.97, 73.65, 62.95, 56.92, 27.37; DEPT-135 (101 MHz, MeOD) δ 127.74, 
127.44, 126.80, 73.66, 62.94, 56.91, 27.37.   
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Using an adapted method of  Badorrey et al.,
111
 n-Bu2SnO (0.032 mmol, 0.029 equiv.) was 
added to a solution of N-Boc protected diol 10 (0.864 mmol, 1 equiv.) in dry CH2Cl2 (3.35 ml) at 
RT under an atmosphere of argon. Subsequently, a solution of Et3N (1.039 mmol, 1.2 equiv.) in 
dry CH2Cl2 (3.35 ml) and TsCl (1.039 mmol, 1.2 equiv.) were added. After 5 h of continuous 
stirring at RT, the reaction mixture was treated with saturated aqueous NaCl solution. The 
organic layer was separated and the aqueous layer was washed three times with CH2Cl2. The 
combined organic layers were washed with brine, and dried over anhydrous MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography (40% EtOAc 
/ hexane; stains purple with ninhydrin) to afford monotosylate 13 as a white solid in 71% yield. 
ESI-MS: m/z 444.139 [M+Na]
+
, 
1
H NMR (400 MHz, CDCl3) δ 7.75  – 7.73  (d, J = 8.1 Hz, 2H), 
7.33 – 7.22 (m, 7H), 5.44 (s, 1H), 4.68 (s, 1H), 4.18 – 4.14 (dd, J = 10.2, 3.5 Hz, 1H), 3.96 (s, 
1H), 3.83 – 3.79 (dd, J = 10.2, 7.1 Hz, 1H), 2.44 (s, 3H), 1.39 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ 155.40, 145.07, 137.57, 132.47, 129.91, 128.66, 127.96, 127.52, 71.06, 64.38, 56.37, 
28.26, 21.63.   
 
Using an adapted method of M.D. Lebar et al.,
112
 a solution of monotosylate 13 (0.593 mmol, 1 
equiv.) in dry CH2Cl2 (5.6 ml) at 0 °C was added 2, 6-lutidine (1.7793 mmol, 3 equiv.) and TBS-
OTf (1.4827 mmol, 2.5 equiv.) under an argon atmosphere. After 2 h of continuous stirring at the 
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same temperature, the reaction mixture was treated with water. The organic layer was separated 
and the aqueous layer was washed two times with CH2Cl2. The combined organic layers were 
washed with water and brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (30% EtOAc / hexane; stains purple 
with ninhydrin) to afford silyl carbamate 3 as a white solid in 59% yield. ESI-MS: m/z 616.320 
[M+Na]
+
, 1H NMR (400 MHz, CDCl3) δ 7.74 – 7.72 (d, J = 8.1 Hz, 2H), 7.34 – 7.27 (m, 7H), 
5.29  – 5.27 (d, J = 8.0 Hz, 1H), 4.68 – 4.65 (dd, J = 8.1, 4.2 Hz, 1H), 4.26 – 4.22 (q, J = 5.2 Hz, 
1H), 3.70 – 3.69 (d, J = 5.7 Hz, 2H), 2.46 (s, 3H), 0.91 – 0.88 (d, J = 9.7 Hz, 18H), 0.27  – 0.23 
(d, J = 17.1 Hz, 6H), 0.05 – 0.04 (d, J = 3.1 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 154.08, 
144.91, 137.18, 132.68, 129.85, 128.49, 128.11, 128.00, 127.94, 71.89, 70.47, 63.59, 56.93, 
25.75, 25.53, 21.63, 18.06, 17.54, -4.61, -4.69, -5.15; DEPT-135 (101 MHz, CDCl3) δ 129.85, 
128.49, 128.12, 128.01, 127.94, 71.89, 70.47, 56.92, 25.75, 25.52, 21.63, -4.61, -4.69, -5.16.   
 
Using an adapted method of Pastó M et al.,
85
 epoxide 8 (1.331mmol, 1eqiv.), NH4OH (2.1 ml, 40 
equiv. of a 30% solution in water), in 4.2 ml of isopropanol were stirred in a sealed tube at 70 °C 
for 48 h. The resulting mixture was concentrated in vacuo to afford amino diol (40% EtOAc / 
hexane; stains purple with ninhydrin) as an oil. The obtained product was converted to the 
hydrochloride salt by treatment with HCl saturated solution of methanol to yield 14 which was 
taken to the next step without purification. 90% yield. ESI-MS: m/z 168.147 [M+H]
+
, 
1
H NMR 
(400 MHz, MeOD) δ 7.55 – 7.43 (m, 5H), 4.49 – 4.48 (d, J = 3.5 Hz, 1H), 4.14 – 4.10 (m, 1H), 
3.43 – 3.39 (dd, J = 11.1, 5.6 Hz, 1H), 3.35 – 3.30 (dd, J = 11.2, 4.8 Hz, 1H); 13C NMR (101 
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MHz, MeOD) δ 133.36, 133.31, 128.75, 128.41, 128.22, 70.85, 62.59, 56.94; DEPT-135 (101 
MHz, MeOD) δ 128.75, 128.41, 128.21, 70.85, 62.59, 56.94. 
 
Using an adapted method of Kamioka et al.,
113
 to a stirred solution of amine salt 14 (4.861 
mmol, 1 equiv.) in anhydrous DMF (12 ml) at 0 °C was added DIEA (13.6108 mmol, 2.8 equiv.) 
and 2,4,6-trimethylbenzene-1-sulfonyl chloride (4.6179 mmol, 0.95 equiv.) under an argon 
atmosphere. The reaction mixture was stirred for 4 h at the same temperature, then treated with 
cold 1M HCl solution and extracted two times with EtOAc. The combined EtOAc layers were 
washed with saturated aqueous NaHCO3 and brine, dried over anhydrous MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography (50% EtOAc 
/ hexane; stains orange with p-anisaldehyde) to afford sulfonamide 15 as a white solid in 58% 
yield. ESI-MS: m/z 372.227 [M+Na]
+
. Melting Point: 116-118 °C. 
1
H NMR (400 MHz, MeOD) 
δ 7.09 – 7.04 (m, 5H), 6.78 (s, 2H), 4.58 (s, 1H), 4.25 – 4.23 (d, J = 6.4 Hz, 1H), 3.87 – 3.83 (q, J 
= 6.0 Hz, 1H), 3.56 – 3.46 (ddt, J = 17.4, 11.4, 5.5 Hz, 2H), 2.47 (s, 6H), 2.19 (s, 3H); 13C NMR 
(101 MHz, MeOD) δ 141.85, 138.53, 137.76, 134.48, 131.30, 127.53, 127.37, 126.79, 73.88, 
63.06, 59.23, 21.77, 19.48; DEPT-135 (101 MHz, MeOD) δ 131.30, 127.53, 127.37, 126.79, 
73.88, 63.06, 59.23, 21.77, 19.48. Elemental Analysis Calcd for C18H23NO4S: C, 61.87; H, 6.63; 
N, 4.01; Found: C, 61.89; H, 6.46; N, 3.96.  
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Using an adapted method of  Kiren et al.,
89
 to a stirred solution of sulfonamide 15 (5.40 mmol, 1 
equiv.) in anhydrous DMF (13 ml) at 0 °C was added imidazole (32.4 mmol, 6 equiv.) and 
TBSCl (24.3 mmol, 4.5 equiv.) under an argon atmosphere. The reaction mixture was stirred for 
48 h at RT, then treated with H2O and extracted three times with Et2O. The combined Et2O 
layers were washed with H2O and brine, dried over anhydrous Na2SO4, filtered and concentrated 
in vacuo. The crude product was purified by column chromatography (15% EtOAc / hexane; 
stains brownish yellow with p-anisaldehyde) to afford bis-silylated 20 in 80% yield. ESI-MS: 
m/z 600.689 [M+Na]
+
,  
1
H NMR (400 MHz, CDCl3) δ 7.09 – 7.06 (m, 5H), 6.74 (s, 2H), 5.95 – 
5.93  (d, J = 6.4 Hz, 1H), 4.45 – 4.43 (m, 1H), 3.91  – 3.87 (dt, J = 8.3, 4.2 Hz, 1H), 3.50  – 3.46 
(dd, J = 10.3, 4.0 Hz, 1H), 3.25  – 3.21 (dd, J = 10.2, 7.6 Hz, 1H), 2.48 (s, 6H), 2.21 (s, 3H), 0.91 
(s, 9H), 0.85 (s, 9H), 0.04 – 0.02 (d, J = 9.0 Hz, 9H), -0.03 (s, 3H); 13C NMR (101 MHz, CDCl3) 
δ 141.50, 138.72, 137.43, 134.58, 131.51, 127.97, 127.60, 127.26, 75.03, 64.65, 60.95, 25.87, 
25.80, 22.86, 22.65, 20.76, 18.19, 18.04, -4.64, -5.03, -5.55, -5.58. Elemental Analysis Calcd for 
C30H51NO4SSi2: C, 62.34; H, 8.89; N, 2.42; Found: C, 61.93; H, 8.75; N, 2.39.   
 
Using an adapted method of Liu et al.,
114
 to a stirred solution of bis-silylated 20 (0.64 mmol, 1 
equiv.) in THF (8 ml) at 0 °C was added H2O (2 ml) and TFA (2 ml). The reaction mixture was 
stirred for 75 min at RT and constantly monitored by TLC. Thereafter, it was treated with the 
saturated aqueous NaHCO3 and extracted three times with DCM. The combined DCM layers 
were washed with H2O and brine, dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by column chromatography (15% EtOAc / hexane; stains 
brownish yellow with p-anisaldehyde) to afford compound 21 as a white solid in 60% yield. ESI-
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MS: m/z 486.381[M+Na]
+
, 
1
H NMR (500 MHz, CDCl3) δ 7.10 (dt, J = 14.0, 6.9 Hz, 3H), 6.99 
(d, J = 7.1 Hz, 2H), 6.76 (s, 2H), 5.84 (d, J = 7.0 Hz, 1H), 4.44 – 4.42 (t, 1H), 3.94 – 3.92 (t, 1H), 
3.75 – 3.73 (d, J = 9.8 Hz, 1H), 3.49 – 3.48 (d, 1H), 2.47 (s, 6H), 2.23 (s, 3H), 0.82 (s, 9H), 0.05 
(s, 3H), -0.09 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 141.86, 138.71, 137.74, 134.33, 131.62, 
127.98, 127.46, 127.43, 74.99, 63.44, 60.68, 25.74, 22.81, 20.78, 18.02, -4.71, -5.08; DEPT-135 
(126 MHz, CDCl3) δ 131.62, 127.98, 127.47, 127.43, 74.98, 63.44, 60.68, 25.75, 22.81, 20.79, -
4.71, -5.08. Elemental Analysis Calcd for C24H37NO4SSi: C, 62.16; H, 8.04; N, 3.02; Found: C, 
62.38; H, 7.95; N, 3.18.  
 
Using an adapted method of  Ghorai et al.,
76
 to a stirred solution of compound 21 (0.25 mmol, 1 
equiv.) and PPh3 (0.375 mmol, 1.5 equiv.) in dry THF (1 ml) was added a solution of DIAD 
(0.375 mmol, 1.5 equiv.) in dry THF (0.5 ml) dropwise at 0 °C over a period of 10 min under an 
argon atmosphere. The resulting mixture was stirred for 2 h at RT. Thereafter, solvent was 
removed under reduced pressure and the crude residue was purified by column chromatography 
(10% EtOAc / hexane; stains brownish orange with p-anisaldehyde) to afford azetidine 22 as a 
white solid in 65% yield. ESI-MS: m/z 468.433 [M+Na]
+
, 
1
H NMR (400 MHz, CDCl3) δ 7.15 – 
7.12 (m, 5H), 6.74 (s, 2H), 4.87 – 4.85  (d, J = 5.7 Hz, 1H), 4.29 – 4.24 (q, J = 6.1 Hz, 1H), 3.92 
– 3.89 (t, J = 6.7 Hz, 1H), 3.85 – 3.82 (t, J = 6.6 Hz, 1H), 2.52 (s, 6H), 2.18 (s, 3H), 0.83 (s, 9H), 
-0.09 – -0.11 (d, J = 7.0 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 142.60, 140.15, 137.63, 131.71, 
131.51, 128.05, 127.90, 126.56, 74.81, 69.61, 55.62, 25.58, 22.91, 20.83, 17.82, -4.82, -5.08; 
DEPT-135 (101 MHz, CDCl3) δ 131.51, 128.05, 127.90, 126.56, 74.81, 69.61, 55.62, 25.58, 
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22.91, 20.83, -4.82, -5.09. Elemental Analysis Calcd for C24H35NO3SSi: C, 64.68; H, 7.92; N, 
3.14; Found: C, 65.38; H, 8.03; N, 3.04.   
 
Using an adapted method of  Saito et al.,
95
 to a stirred solution of mono-alcohol 21 (0.711 mmol, 
1 equiv.) in anhydrous DMSO (3.1 ml) at RT was added IBX (2.844 mmol, 4 equiv.) under an 
argon atmosphere. The resulting mixture was stirred overnight at the same temperature, then it 
was treated with a 1/1 mixture of saturated aqueous NaHCO3 and Na2S2O3 solution and extracted 
three times with Et2O. The combined Et2O layers were washed with brine, dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo to afford pure aldehyde 23 as a white solid in 90% 
yield. ESI-MS: m/z 484.388 [M+Na]
+
, Melting Point: 104-106 °C; 
1
H NMR (500 MHz, CDCl3) 
δ 9.42 (s, 1H), 7.13 – 7.08 (dt, J = 14.1, 6.8 Hz, 3H), 7.02 – 7.01 (d, J = 7.0 Hz, 2H), 6.76 (s, 
2H), 5.62 –5.60 (d, J = 7.7 Hz, 1H), 4.52 – 4.49 (t, 1H), 4.35 – 4.34 (d, J = 4.7 Hz, 1H), 2.48 (s, 
6H), 2.21 (s, 3H), 0.86 (s, 9H), 0.02 (s, 3H), -0.04 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 
201.22, 142.17, 138.81, 135.98, 131.74, 128.14, 128.03, 127.75, 79.95, 58.97, 25.73, 25.66, 
22.80, 20.76, 18.07, -4.82, -5.25; DEPT-135 (126 MHz, CDCl3) δ 201.24, 131.74, 128.13, 
128.03, 127.75, 79.95, 58.96, 25.66, 22.80, 20.76, -4.83, -5.25. 
 
Using an adapted method of  Hirose et al.,
77
 to a stirred solution of aldehyde 23 (0.368 mmol, 1 
equiv.) in anhydrous Et2O (3.68 ml) at -78 °C was added 1.0M solution of vinylmagnesium 
bromide in THF (1.104 mmol, 3 equiv.) dropwise under an argon atmosphere. The resulting 
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mixture was stirred for 7 h at the same temperature, then it was treated with a 1/1 mixture of 
saturated aqueous NaHCO3 and Et2O. The organic layer was separated and washed with NH4Cl, 
H2O, and brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to furnish 
compound 25 (total yield 81%). ESI-MS: m/z 512.46 [M+Na]
+
; 
1
H NMR (500 MHz, CDCl3) δ 
7.07 – 6.97 (m, 10H), 6.73 – 6.70 (d, J = 15.0 Hz, 4H), 6.63 – 6.62 (d, J = 5.0 Hz, 1H), 6.00 – 
5.93 (ddd, J = 17.0, 10.4, 6.2 Hz, 1H), 5.87 – 5.81 (ddd, J = 16.2, 10.6, 4.9 Hz, 1H), 5.58 – 5.56 
(d, J = 8.1 Hz, 1H), 5.31 – 5.25 (dd, J = 17.0, 12.1 Hz, 2H), 5.22  – 5.19 (dd, J = 10.3, 5.1 Hz, 
2H), 4.55 – 4.53 (t, J = 5.3 Hz, 1H), 4.45 – 4.42 (t, 1H), 4.26 (s, 1H), 4.12 – 4.05 (dt, J = 21.2, 
5.2 Hz, 2H), 3.82 – 3.81 (d, J = 5.1 Hz, 1H), 2.46 –2.45 (d, J = 5.9 Hz, 12H), 2.20 – 2.19 (d, J = 
8.2 Hz, 6H), 1.45 (s, 1H), 0.84 – 0.83 (d, J = 3.1 Hz, 18H), 0.10 (s, 3H), 0.02 (s, 3H), -0.07 (s, 
3H), -0.22 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 141.78, 141.46, 138.59, 138.50, 138.30, 
137.70, 137.43, 137.08, 135.23, 134.36, 131.76, 131.59, 131.50, 127.92, 127.85, 127.79, 127.74, 
127.59, 127.55, 127.35, 127.30, 117.40, 116.46, 78.50, 76.32, 74.13, 72.49, 61.65, 59.81, 30.36, 
25.97, 25.88, 25.76, 25.72, 25.67, 25.57, 22.79, 20.73, 18.16, 18.06,  -4.09, -4.53, -4.62, -5.00; 
DEPT-135 (126 MHz, CDCl3) δ 137.42, 137.07, 131.59, 131.50, 127.92, 127.85, 127.79, 127.60, 
127.35, 127.30, 117.41, 116.46, 78.49, 76.30, 74.13, 72.50, 61.65, 59.81, 25.98, 25.88, 22.79, 
20.73, -4.53, -4.62.  
 
Using an adapted method of  Chattopadhyay et al.,
98
 to a cold (10 °C ) and stirred solution of  
compound 23 (0.547 mmol, 1 equiv.), Zn dust (1.367 mmol, 2.5 equiv.) and allyl bromide (1.367 
mmol, 2.5 equiv.) in THF (0.5 mL) was added a saturated aqueous solution of NH4Cl (0.3 mL) 
dropwise via syringe over a period of 30 min. under argon atmosphere. The mixture was stirred 
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for 3 h at RT, filtered, and the precipitate was washed with DCM. The aqueous layer was 
separated and treated with 5% HCl and extracted three times with DCM. The combined DCM 
layers were washed with 10% NaHCO3, H2O and brine, dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by column chromatography (15-20% 
EtOAc / hexane; stains dark purple with p-anisaldehyde) to afford compound 26A and 26B.  
Compound (±)-26A: 15% yield. ESI-MS: m/z 504.402 [M+H]
+
, 
1
H NMR (400 MHz, CDCl3) δ 
7.10 – 7.06 (d, J = 7.2 Hz, 3H), 7.04 – 7.01 (m, 2H), 6.74 (s, 2H), 6.63 – 6.63 (d, J = 5.1 Hz, 1H), 
5.63 – 5.53 (m, 1H), 5.06 – 4.98 (m, 2H), 4.66 –4.63 (t, J = 5.0 Hz, 1H), 3.73 – 3.71 (m, 1H), 
2.45 (s, 6H), 2.21 (s, 3H), 2.16 – 2.10 (dt, J = 14.0, 5.8 Hz, 2H), 0.90 (s, 9H), 0.08 (s, 3H), -0.05 
(s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 141.38, 138.36, 138.20, 135.51, 134.01, 131.50, 128.02, 
127.33, 127.23, 118.04, 74.97, 70.09, 62.16, 38.55, 25.87, 22.82, 20.76, 18.07, -4.56, -4.81; 
DEPT-135 (101 MHz, CDCl3) δ 134.01, 131.50, 128.02, 127.33, 127.23, 118.04, 74.97, 70.09, 
62.16, 38.55, 25.87, 22.82, 20.76, -4.56, -4.81. 
Compound (±)-26B: 55% yield. ESI-MS: m/z 504.462 [M+H]
+
, 
1
H NMR (500 MHz, CDCl3) δ 
7.07 – 7.05 (t, J = 7.3 Hz, 3H), 6.99 – 6.98 (d, J = 7.0 Hz, 2H), 6.74 (s, 2H), 5.79 – 5.71 (td, J = 
16.6, 8.3 Hz, 1H), 5.40 – 5.38 (d, J = 8.3 Hz, 1H), 5.14 – 5.11 (t, 2H), 4.45 – 4.42 (dd, J = 8.1, 
5.4 Hz, 1H), 4.07 – 4.05 (t, J = 5.2 Hz, 1H), 3.54 – 3.49 (dq, J = 11.9, 6.7, 5.8 Hz, 1H), 2.46 (s, 
6H), 2.22 (s, 3H), 1.29 (s, 1H), 0.87 (s, 9H), 0.83 (s, 2H), 0.14 (s, 3H), 0.04 (s, 3H); 
13
C NMR 
(126 MHz, CDCl3) δ 141.87, 138.65, 137.74, 134.80, 134.23, 131.64, 127.98, 127.93, 127.80, 
127.42, 118.63, 78.40, 71.51, 59.64, 37.29, 26.01, 22.80, 20.77, 18.25, -4.15, -4.24; DEPT-135 
(126 MHz, CDCl3) δ 134.80, 131.65, 127.93, 127.80, 127.42, 118.64, 78.39, 71.50, 59.64, 37.29, 
26.01, 22.80, 20.77, -4.15, -4.24. 
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The same procedure was used for the synthesis of 22 was followed using compound 25 (0.247 
mmol, 1 equiv.), PPh3 (0.3705 mmol, 1.5 equiv.), dry THF (1 ml), DIAD (0.3705 mmol, 1.5 
equiv.), and dry THF ((0.5 ml) for DIAD). Chromatographic purification (10%-15% EtOAc / 
hexane; stains brownish orange with p-anisaldehyde) furnished fully substituted azetidine 27 as a 
white solid (total yield 60%). 
Compound (±)-27A: White solid. 35% yield. ESI-MS: m/z 494.458 [M+Na]
+
, Melting Point: 71-
74 °C; 
1
H NMR (400 MHz, CDCl3) δ 7.20 – 7.18 (d, J = 7.8 Hz, 5H), 6.74 (s, 2H), 5.97 – 5.89 
(ddd, J = 17.5, 10.3, 7.6 Hz, 1H), 5.35 – 5.31 (d, J = 17.2 Hz, 1H), 5.18 – 5.16 (d, J = 10.3 Hz, 
1H), 4.75 – 4.73 (d, J = 5.9 Hz, 1H), 4.50 – 4.46 (t, 1H), 3.95 – 3.92 (t, J = 5.9 Hz, 1H), 2.54 (s, 
6H), 2.19 (s, 3H), 0.82 (s, 9H), -0.11 (s, 3H), -0.14 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
142.75, 140.35, 137.86, 135.35, 131.64, 131.50, 128.08, 127.88, 126.85, 118.46, 71.71, 69.72, 
25.55, 22.99, 20.85, 17.81, -4.77; DEPT-135 (101 MHz, CDCl3) δ 135.35, 131.54, 131.50, 
128.08, 127.88, 126.85, 118.46, 76.77, 71.71, 69.72, 25.55, 22.99, 20.85, -4.77. 
 Compound (±)-27B: White solid. 23% yield. ESI-MS: m/z 494.32 [M+Na]
+
, Melting Point: 94-
96 °C; 
1
H NMR (500 MHz, CDCl3) δ 7.08 – 7.00 (dt, J = 22.2, 9.0 Hz, 5H), 6.65 (s, 2H), 6.62 – 
6.57 (m, 1H), 5.48  – 5.46 (d, J = 10.1 Hz, 1H), 5.44  – 5.41 (d, J = 17.0 Hz, 1H), 5.13  – 5.12 (d, 
J = 6.0 Hz, 1H), 4.88  – 4.85 (dd, J = 9.7, 6.9 Hz, 1H), 4.37  – 4.35 (t, J = 6.4 Hz, 1H), 2.50 (s, 
6H), 2.16 (s, 3H), 0.81 (s, 9H), -0.12 (s, 3H), -0.14 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 
142.13, 139.71, 137.14, 134.02, 132.63, 131.26, 127.86, 127.76, 126.44, 120.72, 74.41, 73.41, 
72.52, 25.53, 22.79, 20.74, 17.96, -4.92, -5.07; DEPT-135 (126 MHz, CDCl3) δ 132.62, 131.25, 
127.85, 127.75, 126.44, 120.73, 74.41, 73.41, 72.52, 25.53, 22.79, 20.74, -4.92. 
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Using an adapted method of Sheddan et al.,
115
 a stirred solution of azetidine 27A (0.212 mmol, 1 
equiv.) and Tridecane (0.848 mmol, 4 equiv.) in degassed DCM (11 ml)  was added a solution of 
Grubbs’ II generation catalyst (7 mol %, 0.0148 mmol) in degassed DCM (3 ml). Degassing of 
DCM was carried out by 3 cycles of the freeze and pump technique. The reaction mixture was 
refluxed at 40 °C for 48 h. Thereafter, the solvent was evaporated under reduced pressure and the 
crude product was purified by column chromatography (5%-10% EtOAc / hexane; stains bluish 
grey with p-anisaldehyde) to afford compound 28 as oil in 70% yield. ESI-MS: m/z 648.63 
[M+Na]
+
, 
1
H NMR (500 MHz, CDCl3) δ 7.23 – 7.20 (m, 5H), 6.76 (s, 2H), 5.74 – 5.68 (dt, J = 
13.6, 6.4 Hz, 1H), 5.50 – 5.45 (dd, J = 14.9, 8.1 Hz, 1H), 4.79 – 4.78 (d, J = 5.7 Hz, 1H), 4.41 – 
4.39 (t, 1H), 3.93 – 3.90 (t, J = 5.7 Hz, 1H), 2.56 (s, 6H), 2.20 (s, 3H), 1.95 (s, 2H), 1.30 (s, 
18H), 0.93 – 0.90 (t, J = 6.8 Hz, 3H), 0.83 (s, 9H), -0.11 – -0.12 (d, J = 6.5 Hz, 6H); 13C NMR 
(126 MHz, CDCl3) δ 142.57, 140.33, 138.25, 135.92, 131.99, 131.48, 128.11, 127.85, 127.15, 
126.84, 77.22, 71.17, 69.88, 32.25, 31.98, 29.74, 29.70, 29.67, 29.57, 29.41, 29.16, 28.96, 25.68, 
25.60, 25.53, 23.02, 22.74, 20.87, 17.86, 14.18, -4.75; DEPT-135 (126 MHz, CDCl3) δ 135.93, 
131.48, 128.11, 127.85, 127.15, 126.84, 77.22, 71.16, 69.89, 32.26, 31.98, 29.74, 29.71, 29.67, 
29.57, 29.42, 29.17, 28.96, 25.60, 23.03, 22.99, 22.75, 20.88, 14.20, -4.75.   
 
Using an adapted method of Yajima et al.,
68
 sodium (0.76 mmol, 8 equiv.) was added to the 
solution of naphthalene (0.95 mmol, 10 equiv.) in dry DME (1 ml) under an argon atmosphere. 
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The mixture was stirred for 90 min. at RT. The resulting mixture was added dropwise via syringe 
to a mixture of compound 28 (0.095 mmol, 1 equiv.) in dry DME (0.5 ml) at -78 °C under an 
argon. The reaction mixture was stirred for 40 min. at the same temperature and then treated with 
water. After stirring for 30 min, the reaction mixture was extracted thrice with DCM. The 
combined DCM layers were washed with brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography (20%-40% 
EtOAc / hexane; greyish blue with p-anisaldehyde) to afford compound 29 in 42% yield. ESI-
MS: m/z 444.44 [M+H]
+
.  
Using an adapted method of Wang et al. and Burtoloso et al.,
116, 117
  to a stirred solution 
of compound 29 (0.022 mmol, 1 equiv.) in dry THF (0.5 ml) at 0 °C was added 1.0 M solution of 
TBAF in THF (0.033 mmol, 1.5 equiv.) and the resulting mixture was stirred for overnight at 
RT. Then it was treated with the saturated aqueous NaHCO3 and extracted thrice with DCM. The 
combined DCM layers were washed with brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography (100% 
EtOAc; stains greyish blue with p-anisaldehyde) to afford azetidine alcohol. The obtained 
product was converted to the hydrochloride salt by treatment with HCl saturated solution of 
methanol to furnish 30 as a solid in 40% yield. The product was confirmed based on MS, 
1
H-
NMR and 
13
C-NMR evaluation. ESI-MS: m/z 330.26 [M+H]
+
, 
1
H NMR (400 MHz, CDCl3) δ 
7.43 – 7.33 (m, 5H), 5.91 – 5.78 (qd, J = 16.2, 15.8, 6.2 Hz, 2H), 4.72 – 4.70 (d, J = 5.5 Hz, 1H), 
4.38 – 4.35 (t, 1H), 4.31 – 4.28 (t, 1H), 2.19 – 2.14 (q, 2H), 1.99 (s, 1H), 1.27 (s, 18H), 0.90 – 
0.86 (t, 3H); DEPT-135 (101 MHz, CDCl3) δ 136.46, 128.43, 127.35, 126.60, 125.94, 74.59, 
70.02, 63.69, 32.68, 31.92, 29.68, 29.64, 29.61, 29.50, 29.35, 29.29, 29.24, 22.69, 14.11. 
64 
 
 
The above procedure used in the synthesis of compound 30 was followed using compound 28 
(0.0592 mmol, 1 equiv.) dry THF (1.42 ml) and 1.0 M solution of TBAF in THF (0.0592 mmol, 
1 equiv.). Chromatographic purification (100% EtOAc; stains greyish blue with p-anisaldehyde) 
furnished compound 31 as a white solid in 56% yield. ESI-MS: m/z 534.38 [M+Na]
+
. 
1
H NMR 
(400 MHz, CDCl3) δ 7.23 – 7.18 (dq, J = 6.9, 3.9 Hz, 5H), 6.75 (s, 2H),  5.71 – 5.64 (dt, J = 13.6, 
6.6 Hz, 1H), 5.47 – 5.42 (dd, J = 15.4, 7.8 Hz, 1H),  4.80 – 4.78 (d, J = 6.0 Hz, 1H), 4.41  – 4.38 
(t, 1H), 3.94  – 3.93 (d, J = 5.7 Hz, 1H), 2.98  – 2.96 (d, J = 6.7 Hz, 1H), 2.52 (s, 6H), 2.18 (s, 
3H), 1.91 – 1.90 (d, 2H), 1.27 (s, 18H), 0.90 – 0.87 (t, J = 6.5 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 142.81, 140.40, 138.11, 136.03, 131.59, 131.56, 128.22, 127.98, 126.89, 126.62, 76.55, 
71.00, 69.72, 32.23, 31.94, 29.72, 29.67, 29.64, 29.53, 29.38, 29.20, 28.83, 23.00, 22.70, 20.88, 
14.13; DEPT-135 (101 MHz, CDCl3) δ 136.03, 131.56, 128.22, 127.98, 126.89, 126.63, 76.55, 
71.00, 69.72, 32.22, 31.94, 29.71, 29.67, 29.64, 29.53, 29.37, 29.20, 28.83, 23.00, 22.70, 20.88, 
14.13. 
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